Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 9313 - 9320 of 12007 results

Toy Safety Regulation Should Be Left To The Federal Government

June 25, 2015| Blog| Viewpoint

Crowdfunding and IP in Health and Biotech Start-ups (Part 2): The JOBS Act

June 25, 2015| Blog| Viewpoint

Massachusetts Health Care Regulatory Review – Opportunity for Industry Comment

June 25, 2015| Blog| Viewpoint

Recognizable Faces Disappear from Facial Recognition Meetings

June 25, 2015| Blog| Viewpoint

The Consequences of Waiving the Attorney-Client Privilege

June 24, 2015| Blog| Viewpoint

Federal Circuit Invalidates Diagnostic Method Claims for Prenatal Test Under 35 U.S.C. 101

June 24, 2015| Alert| Viewpoint

Restoration of Visa Issuance at Some Posts

June 24, 2015| Alert| Viewpoint

Newsflash, Politico: 'Patent Death Squad' Alive and Well

June 24, 2015| Blog| Viewpoint

News & Press Releases

Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering

July 08, 2025

Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“

Mintz Advises S2G Investments on $40M Series B Financing of Sojo Industries

July 07, 2025

Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.

Mintz Advises Syntis Bio on $33 Million Series A Financing

July 02, 2025

Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.

View all News and Press Releases